Effective Pathway to the α-CF3-Substituted Azahistidine Analogues

Grigorii T. Shchetnikov; Alexander S. Peregudov; Sergej N. Osipov

doi:10.1055/s-2006-956492

LETTER

Effective Pathway to the α-CF₃-Substituted Azahistidine Analogues

Grigorii T. Shchetnikov, Alexander S. Peregudov, Sergej N. Osipov*
A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov str. 28, 119991 Moscow, Russia
Fax: +7(495)1355085; e-Mail: osipov@ineos.ac.ru;

Abstract

All articles of this category

Abstract

An efficient method for the preparation of functionalized α-trifluoromethyl-substituted azahistidine analogues has been developed. The method is based on the regioselective addition of allenylmagnesiumbromide to highly electrophilic imines of trifluoropyruvates and subsequent 1,3-dipolar Huisgen cycloaddition between α-propargyl-α-trifluoromethyl-α-amino esters and organic azides.

Key words

fluorinated imines - amino acids - histidine - click reaction - organic azides

Full Text

References

References and Notes

<A NAME="RG30706ST-1A">1a</A> Giannis A. Kolter T. Angew. Chem., Int. Ed. Engl. 1993, 32: 1244

<A NAME="RG30706ST-1B">1b</A> Seebach D. Sting AR. Hoffmann M. Angew. Chem., Int. Ed. Engl. 1996, 35: 2708

<A NAME="RG30706ST-1C">1c</A> Cativiela C. Diaz-de-Villegas MD. Tetrahedron: Asymmetry 1998, 9: 3517

<A NAME="RG30706ST-1D">1d</A> Link AJ. Mock ML. Tirrell DA. Curr. Opin. Biotechnol. 2003, 14: 603

<A NAME="RG30706ST-2A">2a</A> Sewald N. Burger K. In Synthesis of β-Fluoro-Containing Amino Acids Kukhar’ VP. Soloshonok VA. John Wiley and Sons Ltd.; New York: 1995. p.139

<A NAME="RG30706ST-2B">2b</A> Yoder NC. Kumar K. Chem. Soc. Rev. 2002, 31: 335

<A NAME="RG30706ST-2C">2c</A> Jaeckel C. Salwiczek M. Koksch B. Angew. Chem. Int. Ed. 2006, 45: 4198

<A NAME="RG30706ST-3A">3a</A> Gregory DH. Gerig JT. Biopolymers 1991, 31: 845

<A NAME="RG30706ST-3B">3b</A> Cushmann M. Patel HH. Scheuring J. Bacher A. J. Org. Chem. 1992, 57: 5630

<A NAME="RG30706ST-4">4</A> Kollonitsch J. In Biomedicinal Aspects of Fluorine Chemistry Filler R. Kobayashi Y. Kondasha, Tokyo and Elsevier Biomedical Press; Amsterdam: 1982. p.93 ; and references cited therein

<A NAME="RG30706ST-5A">5a</A> Osipov SN. Golubev AS. Sewald N. Burger K. Tetrahedron Lett. 1997, 38: 5965

<A NAME="RG30706ST-5B">5b</A> Moroni M. Koksch B. Osipov SN. Crucianelli M. Triderio M. Bravo P. Burger K. J. Org. Chem. 2001, 66: 130

<A NAME="RG30706ST-5C">5c</A> Osipov SN. Tsouker P. Hennig L. Burger K. Tetrahedron 2004, 60: 271

<A NAME="RG30706ST-6">6</A> Osipov SN. Golubev AS. Sewald N. Michel T. Kolomiets AF. Fokin AV. Burger K. J. Org. Chem. 1996, 61: 7521

<A NAME="RG30706ST-7A">7a</A> Osipov SN. Bruneau C. Picquet M. Kolomiets AF. Dixneuf PH. Chem. Commun. 1998, 2053

<A NAME="RG30706ST-7B">7b</A> Semeril D. Le Notre J. Bruneau C. Dixneuf PH. Kolomiets AF. Osipov SN. New J. Chem. 2001, 16

<A NAME="RG30706ST-7C">7c</A> Osipov SN. Artyushin OI. Kolomiets AF. Bruneau C. Dixneuf RH. Synlett 2000, 1031

<A NAME="RG30706ST-7D">7d</A> Osipov SN. Kobel’kova NM. Shchetnikov GT. Kolomiets AF. Bruneau C. Dixneuf PH. Synlett 2001, 621

<A NAME="RG30706ST-7E">7e</A> Osipov SN. Artyushin OI. Kolomiets AF. Bruneau C. Picquet M. Dixneuf PH. Eur. J. Org. Chem. 2001, 3891

<A NAME="RG30706ST-7F">7f</A> Osipov SN. Dixneuf P. Russ. J. Org. Chem. 2003, 39: 1211

<A NAME="RG30706ST-7G">7g</A> Eckert M. Monnier F. Shchetnikov GT. Titanyuk ID. Osipov SN. Dérien S. Dixneuf PH. Org. Lett. 2005, 7: 3741

<A NAME="RG30706ST-8A">8a</A> Faden AI. Labroo VM. Cohen LA. Neurotrauma 1993, 10: 101

<A NAME="RG30706ST-8B">8b</A> Vonhof S. Paakkari I. Feuerstein G. Cohen LA. Labroo VM. Eur. J. Pharmacol. 1989, 164: 77

<A NAME="RG30706ST-8C">8c</A> Narayanan S. Vangapandu S. Jain R. Bioorg. Med. Chem. Lett. 2001, 11: 1133

<A NAME="RG30706ST-9">9</A> Kolb HC. Finn MG. Sharpless KB. Angew. Chem. Int. Ed. 2001, 40: 2004

<A NAME="RG30706ST-10">10</A> Bock VD. Hiemstra H. van Maarseveen JH. Eur. J. Org. Chem. 2006, 51

<A NAME="RG30706ST-11">11</A> Alvarez R. Velazquez S. San-Felix A. Aquaro S. De Clercq E. Perno C.-F. Karlsson A. Balzarini J. Carmarasa MJ. J. Med. Chem. 1994, 37: 4185

<A NAME="RG30706ST-12">12</A> Brockunier LL. Parmee ER. Ok HO. Candelore MR. Cascieri MA. Colwell LF. Deng L. Feeney WP. Wyvratt MJ. Fisher MH. Weber AE. Bioorg. Med. Chem. Lett. 2000, 10: 2111

<A NAME="RG30706ST-13">13</A> Genin MJ. Allwine DA. Anderson DJ. Barbachyn MR. Emmert DE. Garmon SA. Graber DR. Grege KC. Hester JB. Hutchinson DK. Morris J. Reischer RJ. Ford CW. Zurenko GE. Hamel JC. Schaadt RD. Stapert D. Yagi BH. J. Med. Chem. 2000, 43: 953

<A NAME="RG30706ST-14A">14a</A> Buckle DR. Rockell CJM. J. Chem. Soc., Perkin Trans. 1 1982, 627

<A NAME="RG30706ST-14B">14b</A> Buckle DR. Outred DJ. Rockell CJM. Smith H. Spicer BA. J. Med. Chem. 1983, 26: 251

<A NAME="RG30706ST-14C">14c</A> Buckle DR. Rockell CJM. Smith H. Spicer BA. J. Med. Chem. 1986, 29: 2262

<A NAME="RG30706ST-15">15</A> For cytokine inhibition, see: Kim D.-K. Park HJ. Bioorg. Med. Chem. Lett. 2004, 14: 2401

General Procedure for the Preparation of 2.
Allenylmagnesiumbromide¹⁷ (solution in THF, 10.0 mmol) was added dropwise to a stirred solution of an imine (10.0 mmol) in dry THF (25 mL) at -78 °C. After 1 h at -78 °C the reaction mixture was allowed to warm to r.t. within 2 h. The reaction was quenched with 1 N HCl and extracted with Et₂O (2 × 25 mL). The combined organic layer was washed with brine (25 mL), dried over MgSO₄ and filtered. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (EtOAc-PE).
Data for Compounds 2a,b. Compound 2a: oil. ¹H NMR (300 MHz, CDCl₃): δ = 2.09 (s, 1 H, ºCH), 3.10 (d, J _AB = 16.6 Hz, 1 H, CH₂), 3.71 (d, J _AB = 16.6 Hz, 1 H, CH₂), 3.96 (s, 3 H, OCH₃), 5.22 (m, 2 H, OCH₂), 6.10 (s, 1 H, NH), 7.43 (m, 5 H, Ph). ¹⁹F NMR (282 MHz, CDCl₃): δ (TFA) = 3.38 (s, 3 F, CF₃). Anal. Calcd for C₁₅H₁₄F₃NO₄ (%): C, 54.71; H, 4.29; F, 17.33. Found: C, 55.02; H, 4.38; F, 16.99.
Compound 2b: mp 70-71 °C. ¹H NMR (300 MHz, CDCl₃): δ = 1.46 [s, 9 H, C(CH₃)₃], 2.06 (s, 1 H, ºCH), 3.10 (d_, J = 16.9 Hz, 1 H, CH₂), 3.71 (m, 1 H, CH₂), 3.90 (s, 3 H, OCH₃), 5.70 (s, 1 H, NH). ¹⁹F NMR (282 MHz, CDCl₃): δ (TFA) = 3.44 (s, 3 F, CF₃). Anal. Calcd for C₁₂H₁₆F₃NO₄: C, 48.81; H, 5.47; N, 4.74. Found: C, 48.74; H, 5.47; N, 4.68.

<A NAME="RG30706ST-17">17</A> Brandsma L. Verkrujsse H. Preparative Organometallic Chemistry Vol. 1: Springer; Berlin: 1987. p.63

See, for example:

<A NAME="RG30706ST-18A">18a</A> Kuijpers BHM. Groothuys S. Keereweer AR. Quaedflieg PJLM. Blaauw RH. Van Delft FL. Rutjes FPJT. Org. Lett. 2004, 6: 3123

<A NAME="RG30706ST-18B">18b</A> Horne WS. Stout CD. Ghadiri MR. J. Am. Chem. Soc. 2003, 125: 9372

<A NAME="RG30706ST-18C">18c</A> Dondoni A. Giovannini PP. Massi A. Org. Lett. 2004, 6: 2929

<A NAME="RG30706ST-18D">18d</A> Angelo NG. Arora PS. J. Am. Chem. Soc. 2005, 127: 17134

<A NAME="RG30706ST-18E">18e</A> Paul A. Bittermann H. Gmeiner P. Tetrahedron 2006, 62: 8919

Typical Procedure for the Preparation of 3. Method A. A mixture of organic azide (1.0 mmol), amino ester 2 (1.0 mmol), DIPEA (3.0 mmol) and CuI (0.1 mmol) in THF (10 mL) was stirred at r.t. for 6-8 h. The resulted reaction mixture was treated with 1 N HCl (15 mL), and extracted with Et₂O (3 × 15 mL). Combined organic layers were dried over MgSO₄ and filtered. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography on silica gel (EtOAc-PE). Method B. Organic azide (2.0 mmol) and amino ester 2 (2.0 mmol) were suspended in 1:1 H₂O-t-BuOH (8 mL). To this was added CuSO₄·5H₂O (5 M solution, 0.1 mmol, 5 mol%) and sodium ascorbate (0.6 mmol). The mixture was stirred at r.t. for 24 h, at which time TLC (silica, PE-EtOAc) indicated complete conversion. The resulted solution was concentrated under reduced pressure (rotary evaporator). The residue was dissolved in 30 mL of brine and then extracted with CH₂Cl₂ (3 × 30 mL). Combined organic layers were washed with 5% aq NH₄OH (2 × 10 mL), dried over MgSO₄, filtered and solvent was removed under vacuum to give analytically pure product.
Data for Compounds 3a,g. Compound 3a: mp 158-159 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.80 (d, 1 H, CH₂, J _AB = 15.0 Hz), 4.03 (s, 3 H, OCH₃), 4.16 (d, 1 H, CH₂, J _AB = 15.0 Hz), 6.18 (s, 1 H, NH), 7.53-7.90 (m, 10 H, Ar), 8.22 (s, 1 H, H-triazole). ¹⁹F NMR (282 MHz, CDCl₃): δ (TFA) = 5.38 (s, 3 F, CF₃). Anal. Calcd for C₁₉H₁₇F₃N₄O₄S (%): C, 50.22; H, 3.77; N, 12.33. Found: C, 50.07; H, 3.84; N, 12.28.
Compound 3g: mp 78-79 °C. ¹H NMR (300 MHz, CDCl₃): δ = 1.84 and 1.88 (2 × s, 3 H, OAc), 2.12 (m, 9 H, 3 × OAc), 3.67 (dd, J = 14.8, 2.5 Hz, 1 H, CH), 3.95 and 3.98 (2 × s, 3 H, OMe), 4.02 (m, 1 H, CH), 4.26 (m, 3 H, CH, CH₂), 5.11-5.51 (m, 5 H, 3 × CH, OCH₂), 5.78 (t, ² J _H-H = 8.9 Hz, 1 H), 6.09 (br s, 1 H, NH), 7.45 (m, 6 H, 1 H-triazole, 5 H-Ar). ¹⁹F NMR (282 MHz, CDCl₃): δ (TFA) = 3.87 (br s, 3 F, CF₃). Anal. Calcd for C₂₉H₃₃F₃N₄O₁₃: C, 49.58; H, 4.73; N, 7.97. Found: C, 49.12; H, 4.57; N, 7.57.

Data for Compound 6.
Mp 216-217 °C. ¹H NMR (300 MHz, D₂O): δ = 3.38 (d, J _AB = 15.3 Hz, 1 H), 3.64 (d, J _AB = 15.3 Hz, 1 H), 7.73 (s, 1 H, H-triazole). ¹⁹F NMR (282 MHz, D₂O): δ (TFA) = 3.55 (s, 3 F, CF₃). ¹³C NMR (150.9 MHz, D₂O): δ = 26.5, 65.3 (q, ² J _C-F = 25.4 Hz), 123.5 (q, ¹ J _C-F = 228.9 Hz), 128.1, 137.9, 166.0. Anal. Calcd for C₆H₇F₄N₄O₂: C, 32.15; H, 3.15; N, 25.00. Found: C, 32.12; H, 3.04; N, 24.67.